Neuronetics to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call
25 Julho 2023 - 9:30AM
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical
technology company focused on designing, developing, and marketing
products that improve the quality of life for patients who suffer
from neurohealth disorders, today announced that it plans to
release second quarter 2023 financial and operating results prior
to market open on Tuesday, August 8th, 2023. The Company will host
a conference call to review its results at 8:30 a.m. Eastern
Time the same day.
The conference call will be broadcast live in listen-only mode
via webcast at
https://edge.media-server.com/mmc/p/papp9yri. To
listen to the conference call on your telephone, participants may
register for the call here. While it is not
required, it is recommended you join 10 minutes prior to the event
start.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as
physical health. As a global leader in neuroscience, Neuronetics is
redefining patient and physician expectations with its NeuroStar
Advanced Therapy for Mental Health. NeuroStar is a non-drug,
noninvasive treatment that can improve the quality of life for
people suffering from neurohealth conditions when traditional
medication hasn’t helped. NeuroStar is FDA-cleared for adults with
major depressive disorder (MDD), as an adjunct for adults with
obsessive-compulsive disorder (OCD), and to decrease anxiety
symptoms in adult patients with MDD that may exhibit comorbid
anxiety symptoms (anxious depression). NeuroStar Advanced Therapy
is the leading transcranial magnetic stimulation (TMS) treatment
for MDD in adults with over 5.4 million treatments delivered.
NeuroStar is backed by the largest clinical data set of any TMS
system for depression, including the world’s largest depression
Outcomes Registry. Neuronetics is committed to transforming lives
by offering an exceptional treatment that produces extraordinary
results. For safety and prescribing information,
www.neurostar.com.
Investor Contact:Mike Vallie or Mark
KlausnerICR Westwicke443-213-0499ir@neuronetics.com
Media
Contact:EvolveMKD646-517-4220NeuroStar@evolvemkd.com
Neuronetics (NASDAQ:STIM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Neuronetics (NASDAQ:STIM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024